NewAmsterdam Pharma Company NV
NAMSW23.440USD
+0.440+1.91%
Close （ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of NewAmsterdam Pharma Company NV Company
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
NewAmsterdam Pharma Company NV Info
Ticker SymbolNAMSW
Company nameNewAmsterdam Pharma Company NV
IPO dateNov 23, 2022
CEODr. Michael Harvey Davidson, M.D.
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
AddressGooimeer 2-35
CityNAARDEN
Stock exchangeNASDAQ Global Market Consolidated
CountryNetherlands
Postal code1411 DC
Phone31352062971
Websitehttps://ir.newamsterdampharma.com/
Ticker SymbolNAMSW
IPO dateNov 23, 2022
CEODr. Michael Harvey Davidson, M.D.
Company Executives of NewAmsterdam Pharma Company NV
Name
Name/Position
Position
Shareholding
Change
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
--
--
Mr. Wouter Joustra
Mr. Wouter Joustra
Independent Director
Independent Director
--
--
Ms. Adele M. Gulfo
Ms. Adele M. Gulfo
Independent Director
Independent Director
--
--
Dr. Louis Lange, M.D., Ph.D.
Dr. Louis Lange, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Janneke Van Der Kamp
Ms. Janneke Van Der Kamp
Temporary Non-Executive Director
Temporary Non-Executive Director
--
--
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Nicholas Downing, M.D.
Dr. Nicholas Downing, M.D.
Director
Director
--
--
Ms. Louise Kooij
Ms. Louise Kooij
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
--
--
Mr. Wouter Joustra
Mr. Wouter Joustra
Independent Director
Independent Director
--
--
Ms. Adele M. Gulfo
Ms. Adele M. Gulfo
Independent Director
Independent Director
--
--
Dr. Louis Lange, M.D., Ph.D.
Dr. Louis Lange, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Janneke Van Der Kamp
Ms. Janneke Van Der Kamp
Temporary Non-Executive Director
Temporary Non-Executive Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Jan 2
Updated: Fri, Jan 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
24
1.30M
0.00%
-592.22K
2025Q3
26
1.30M
0.00%
-652.78K
2025Q2
26
1.30M
0.00%
-657.22K
2025Q1
28
1.31M
0.00%
-682.10K
2024Q4
31
1.32M
0.00%
-986.85K
2024Q3
38
1.33M
0.00%
-1.41M
2024Q2
50
1.30M
0.00%
-1.97M
2024Q1
49
1.44M
0.00%
-1.61M
2023Q4
46
1.64M
0.00%
-1.32M
2023Q3
45
1.61M
0.00%
-1.70M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Frazier Life Sciences Management, L.P.
500.33K
0%
--
--
Sep 30, 2025
RA Capital Management, LP
333.33K
0%
--
--
Sep 30, 2025
Affinity Asset Advisors LLC
245.00K
0%
--
--
Sep 30, 2025
Bain Capital Life Sciences Investors, LLC
100.00K
0%
--
--
Sep 30, 2025
Deerfield Management Company, L.P.
92.79K
0%
--
--
Sep 30, 2025
Laurion Capital Management LP
16.67K
0%
--
--
Sep 30, 2025
HRT Financial LP
--
0%
-13.65K
-100.00%
Mar 31, 2025
Wolverine Asset Management, LLC
--
0%
-2.09K
-100.00%
Sep 30, 2025
Vestcor Inc
9.63K
0%
--
--
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of NewAmsterdam Pharma Company NV?
The top five shareholders of NewAmsterdam Pharma Company NV are:
Frazier Life Sciences Management, L.P. holds 500.33K shares, accounting for 0.00% of the total shares.
RA Capital Management, LP holds 333.33K shares, accounting for 0.00% of the total shares.
Affinity Asset Advisors LLC holds 245.00K shares, accounting for 0.00% of the total shares.
Bain Capital Life Sciences Investors, LLC holds 100.00K shares, accounting for 0.00% of the total shares.
Deerfield Management Company, L.P. holds 92.79K shares, accounting for 0.00% of the total shares.
Frazier Life Sciences Management, L.P. holds 500.33K shares, accounting for 0.00% of the total shares.
RA Capital Management, LP holds 333.33K shares, accounting for 0.00% of the total shares.
Affinity Asset Advisors LLC holds 245.00K shares, accounting for 0.00% of the total shares.
Bain Capital Life Sciences Investors, LLC holds 100.00K shares, accounting for 0.00% of the total shares.
Deerfield Management Company, L.P. holds 92.79K shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of NewAmsterdam Pharma Company NV?
The top three shareholder types of NewAmsterdam Pharma Company NV are:
Other
Other
How many institutions hold shares of NewAmsterdam Pharma Company NV (NAMSW)?
As of 2025Q4, 24 institutions hold shares of NewAmsterdam Pharma Company NV, with a combined market value of approximately 1.30M, accounting for --% of the total shares. Compared to 2025Q3, institutional shareholding has increased by --.
What is the biggest source of revenue for NewAmsterdam Pharma Company NV?
In --, the -- business generated the highest revenue for NewAmsterdam Pharma Company NV, amounting to -- and accounting for --% of total revenue.
